

Reem Karmali

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7652471/reem-karmali-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

113
papers

1,276
citations

15
h-index

33
g-index

116
ext. papers

1,709
ext. citations

3.1
avg, IF

3.86
L-index

#	Paper	IF	Citations
113	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014 , 124, 2354-61	2.2	306
112	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3141-9	2.2	170
111	A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. <i>Blood</i> , 2012 , 119, 692-5	2.2	113
110	Analysis of very elderly (80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. <i>British Journal of Haematology</i> , 2012 , 156, 196-204	4.5	67
109	Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2019 , 37, 471-480	2.2	44
108	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018 , 124, 2541-2551	6.4	44
107	Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. <i>American Journal of Hematology</i> , 2017 , 92, 161-170	7.1	43
106	Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. <i>British Journal of Haematology</i> , 2016 , 175, 631-640	4.5	41
105	Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. <i>Blood</i> , 2021 , 137, 1318-1326	2.2	25
104	Current overview and treatment of mantle cell lymphoma. <i>F1000Research</i> , 2018 , 7,	3.6	22
103	C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. <i>Cancer</i> , 2017 , 123, 4411-4418	6.4	19
102	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021 , 137, 374-386	2.2	19
101	Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy. <i>Current Treatment Options in Oncology</i> , 2017 , 18, 11	5.4	18
100	Breast implant-associated anaplastic large-cell lymphoma and the role of brentuximab vedotin (SGN-35) therapy: A case report and review of the literature. <i>Molecular and Clinical Oncology</i> , 2017 , 6, 539-542	1.6	16
99	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020 , 4, 253-262	7.8	16
98	Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 467-74	2	14
97	GSK-3 inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents. <i>Oncotarget</i> , 2017 , 8, 114924-114934	3.3	13

96	Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. <i>Journal of Leukocyte Biology</i> , 2013 , 93, 161-70	6.5	13
95	All in the family: Clueing into the link between metabolic syndrome and hematologic malignancies. <i>Blood Reviews</i> , 2015 , 29, 71-80	11.1	12
94	Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas. <i>Annals of Oncology</i> , 2018 , 29, 332-340	10.3	12
93	A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I). <i>Blood</i> , 2018 , 132, 679-679	2.2	12
92	Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. <i>British Journal of Haematology</i> , 2019 , 186, 45-53	4.5	11
91	Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. <i>Cancer</i> , 2020 , 126, 293-303	6.4	11
90	Impact of cachexia on outcomes in aggressive lymphomas. <i>Annals of Hematology</i> , 2017 , 96, 951-956	3	10
89	Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. <i>British Journal of Haematology</i> , 2020 , 191, 44-51	4.5	10
88	Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells. <i>Oncotarget</i> , 2018 , 9, 21166-21181	3.3	9
87	Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Oncologist</i> , 2020 , 25, 878-885	5.7	9
86	Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2097-104	1.9	8
85	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021 , 106, 1932-1942	6.6	8
84	Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 408-414	2	7
83	Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. <i>Cancer</i> , 2019 , 125, 1830-1836	6.4	7
82	Impact of therapeutic regimen and clinical presentation on overall survival in CNS lymphoma. <i>Acta Neurochirurgica</i> , 2014 , 156, 355-65	3	7
81	Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Blood</i> , 2018 , 132, 1626-1626	2.2	7
80	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1129-1138	2.2	7
79	Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy. <i>Oncotarget</i> , 2017 , 8, 58108-58121	3.3	6

78	Impact Of Induction Regimen and Consolidative Stem Cell Transplantation In Patients With Double Hit Lymphoma (DHL): A Large Multicenter Retrospective Analysis. <i>Blood</i> , 2013 , 122, 640-640	2.2	6
77	Allogeneic transplantation in elderly patients ≥ 5 years with non-Hodgkin lymphoma: a time-trend analysis. <i>Blood Cancer Journal</i> , 2019 , 9, 97	7	6
76	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2021 ,	2.2	6
75	Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma. <i>British Journal of Haematology</i> , 2017 , 177, 72-79	4.5	5
74	Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3135-42	1.9	5
73	Revving up the immune engine in cHL. <i>Blood</i> , 2019 , 134, 1-2	2.2	5
72	Prospective Phase I Multi-Center Trial Incorporating Lenalidomide (LEN) into Dose-Adjusted EPOCH Plus Rituximab (DA-EPOCH-R) in Patients with Double Hit (DHL) or Double Expressing (DEL) Lymphomas: Final Results. <i>Blood</i> , 2016 , 128, 4191-4191	2.2	5
71	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021 , 7, 993-1003	13.4	5
70	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021 , 5, 2852-2862	7.8	5
69	Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 672-678	2	5
68	Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. <i>Oncologist</i> , 2020 , 25, e993-e997	5.7	5
67	Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis. <i>Journal of Biological Chemistry</i> , 2021 , 296, 100100	5.4	5
66	Localized bone disease as a presentation of hairy cell leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2008 , 6, 290-4	0.6	5
65	CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions. <i>Blood</i> , 2020 , 136, 27-28	2.2	4
64	Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2020 , 189, 313-317	4.5	4
63	Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers. <i>Blood</i> , 2018 , 132, 451-451	2.2	3
62	Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1099-1105	4.7	3
61	Phase 2 study of CHOP-R-14 followed by Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma. <i>Molecular and Clinical Oncology</i> , 2017 , 6, 627-633	1.6	2

60	Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status. <i>Leukemia and Lymphoma</i> , 2019 , 60, 3266-3271	1.9	2
59	Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis. <i>Blood</i> , 2020 , 136, 4-6	2.2	2
58	Phase II Study of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis. <i>Blood</i> , 2010 , 116, 3947-3947	2.2	2
57	Tri-ethylene glycol modified class B and class C CpG conjugated gold nanoparticles for the treatment of lymphoma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020 , 30, 102290	6	2
56	Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7514-7514	2.2	2
55	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019 , 60, 940-946	1.9	2
54	Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021 , 96, 1374-1384	7.1	2
53	Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. <i>Blood</i> , 2020 , 136, 49-50	2.2	1
52	Prognosis and Outcomes of Patients with Post-Transplant Lymphoproliferative Disorder: A Single Center Retrospective Review. <i>Blood</i> , 2020 , 136, 9-10	2.2	1
51	Relapsed disease: off-the-shelf immunotherapies vs customized engineered products. <i>Hematology American Society of Hematology Education Program</i> , 2021 , 2021, 164-173	3.1	1
50	Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy. <i>Blood</i> , 2018 , 132, 453-453	2.2	1
49	Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). <i>Blood</i> , 2018 , 132, 623-623	2.2	1
48	Favorable Outcomes of Neutropenic Enterocolitis Following Hematopoietic Stem Cell Transplantation (HSCT) Using a Conservative Medical Therapy Approach.. <i>Blood</i> , 2010 , 116, 1283-1283	2.2	1
47	Tolerability of 2-Weekly CHOP+Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan (Zevalin) In Patients with Previously Untreated Diffuse Large B Cell Lymphoma (DLBCL): Final Analysis. <i>Blood</i> , 2010 , 116, 4918-4918	2.2	1
46	Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era. <i>Blood</i> , 2011 , 118, 2625-2625	2.2	1
45	CD20, CD22, CD23, but Not CD37 Expression on CD19+ B-Cells Is Altered by Exogenous Factors in a Sub-Population of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL) Patients., <i>Blood</i> , 2011 , 118, 3685-3685	2.2	1
44	Biologic Pathways of Cancer-Cachexia Syndrome (Muscle and Fat Wasting) Impact Clinical Outcomes in Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 1771-1771	2.2	1
43	Impact of circulating members of the insulin-like growth factor receptor (IGF-1R) axis on outcomes in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7069-7069	2.2	1

42	High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers. <i>Blood</i> , 2021 , 138, 455-455	2.2	1
41	Analysis of Outcomes and Predictors of Response in Patients with Relapsed Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucl. <i>Blood</i> , 2021 , 138, 1756-1756	2.2	1
40	Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial. <i>Blood</i> , 2021 , 138, 229-229	2.2	1
39	Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study. <i>Blood</i> , 2021 , 138, 529-529	2.2	1
38	Diffuse Large B-Cell Lymphomas Transformed from or with Concurrent Follicular Lymphoma Demonstrate Similar Clinical Outcomes As De-Novo Diffuse Large B-Cell Lymphomas, Except for Cases Harboring Double Hit Rearrangements. <i>Blood</i> , 2017 , 130, 828-828	2.2	1
37	Inhibition of Pro-Survival Pathways in DLBCL Cells By Functional Lipoprotein-like Nanoparticles. <i>Blood</i> , 2018 , 132, 1668-1668	2.2	1
36	Identification of a Meta-Gene Network Associated with Metformin Sensitivity and Clinical Outcomes in Double Hit and Double Expressor Lymphomas. <i>Blood</i> , 2015 , 126, 2431-2431	2.2	1
35	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021 , 107, 301-310	3.8	1
34	Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis. <i>Hematological Oncology</i> , 2021 , 39, 473-482	1.3	1
33	A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas. <i>Leukemia and Lymphoma</i> , 2021 , 1-8	1.9	1
32	Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease. <i>Blood</i> , 2020 , 136, 30-31	2.2	0
31	Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucl (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7). <i>Blood</i> , 2021 , 138, 430-430	2.2	0
30	B Cell Lymphomas of the GI Tract. <i>Current Gastroenterology Reports</i> , 2021 , 23, 9	5	0
29	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021 , 5, 5179-5189	7.8	0
28	Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse.. <i>Case Reports in Hematology</i> , 2022 , 2022, 1930546	0.7	0
27	Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20. <i>Chemotherapy</i> , 2017 , 62, 140-146	3.2	
26	Painless Vulvar Masses as Initial Manifestation of Marginal Zone Lymphoma. <i>Journal of Lower Genital Tract Disease</i> , 2018 , 22, 82-84	3.6	
25	Radioimmunotherapy in Lymphomas 2014 , 398-402		

24	Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era. <i>Blood</i> , 2020 , 136, 24-26	2.2
23	PD-L1 Pathway Markers and Chromosome 9p24.1 Alterations in Patients with Classic Hodgkin Lymphoma Treated with Frontline Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy. <i>Blood</i> , 2020 , 136, 17-18	2.2
22	EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort. <i>Blood</i> , 2020 , 136, 4-6	2.2
21	Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience. <i>Blood</i> , 2020 , 136, 14-16	2.2
20	Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study. <i>Blood</i> , 2020 , 136, 5-6	2.2
19	The Burkitt Lymphoma International Prognostic Index (BL-IPI). <i>Blood</i> , 2020 , 136, 46-49	2.2
18	Outcomes of Primary Bone Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multicenter Retrospective Analysis. <i>Blood</i> , 2021 , 138, 1451-1451	2.2
17	A Large Multicenter Real-World Evidence (RWE) Analysis of Autoimmune (AI) Diseases and Lymphoma: Histologic Associations, Disease Characteristics, Survival, and Prognostication. <i>Blood</i> , 2021 , 138, 50-50	2.2
16	Phase I Study of Novel SYK Inhibitor TAK-659 in Combination with R-CHOP for Front-Line Treatment of High Risk Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 3566-3566	2.2
15	Incorporating Target Immunotherapy into Standard Conditioning Regimen Prior to Autologous Stem Cell Transplantation (ASCT) Improves the Transplant Outcome for Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (B-NHL).. <i>Blood</i> , 2007 , 110, 1911-1911	2.2
14	Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2018 , 132, 4153-4153	2.2
13	Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. <i>Blood</i> , 2018 , 132, 93-93	2.2
12	Impact of Routine Surveillance Imaging on Outcomes in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT). <i>Blood</i> , 2015 , 126, 4360-4360	2.2
11	Impact of Routine Surveillance Imaging on Outcomes in Patients with Classical Hodgkin Lymphoma (cHL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT). <i>Blood</i> , 2015 , 126, 3169-3169	2.2
10	Primary Failure Diffuse Large B Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features. <i>Blood</i> , 2016 , 128, 513-513	2.2
9	Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies. <i>Blood</i> , 2016 , 128, 103-103	2.2
8	MYC+ relapsed and refractory (R/R) diffuse large b-cell lymphoma (DLBCL): Impact of additional hits and outcomes with subsequent therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7541-7541	2.2
7	Update on a Prospective Study Evaluating the Safety and Efficacy of Combination Therapy with Fludarabine, Mitoxantrone and Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan and Maintenance Rituximab as Front Line Therapy for Patients with Indolent Lymphomas. <i>Blood</i> , 2010 , 116, 3816-3816	2.2

6	Multicenter Analysis of 150 Very Elderly Non-Hodgkin's Lymphoma (NHL) Patients: Impact of Comorbidities and Response to Initial Therapy on Survival. <i>Blood</i> , 2010 , 116, 3124-3124	2.2
5	Lenalidomide-Induced Cytopenias In Patients with MDS Are Negatively Impacted by Reduced Glomerular Filtration Rate. <i>Blood</i> , 2010 , 116, 4958-4958	2.2
4	Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Exhibit Altered Cytokine Protein Levels in Peripheral Blood Serum. <i>Blood</i> , 2011 , 118, 2646-2646	2.2
3	A Long-Term Follow-up Report on Autologous Hematopoietic Cell Transplant (AuHCT) for Patients with Hodgkin Lymphoma [Limited Utility of Post-Transplant Surveillance Computerized Axial Tomography (CAT scan) and/or PET Scan,. <i>Blood</i> , 2011 , 118, 4205-4205	2.2
2	Panel of serum biomarkers to predict benefit from bevacizumab (BEV) in advanced NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e21069-e21069	2.2
1	A Report On a Phase 2 Trial Of Combination Therapy With Lenalidomide and Azacitidine In Patients With Non-Del 5q, Low Risk MDS. <i>Blood</i> , 2013 , 122, 5232-5232	2.2